دورية أكاديمية
Establishment of a human ovarian clear cell carcinoma cell line mutant in PIK3CB but not PIK3CA.
العنوان: | Establishment of a human ovarian clear cell carcinoma cell line mutant in PIK3CB but not PIK3CA. |
---|---|
المؤلفون: | Hoshino H; Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193, Japan., Inoue D; Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan., Shinagawa A; Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan., Yoshida H; Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193, Japan., Shigeto S; Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan., Matsuda K; Department of Clinical Laboratory Sciences, School of Health Sciences, Shinshu University, Matsumoto, Japan., Akama TO; Department of Pharmacology, Kansai Medical University, Hirakata, Japan., Yoshida Y; Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan., Kobayashi M; Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193, Japan. motokoba@u-fukui.ac.jp. |
المصدر: | Human cell [Hum Cell] 2024 Jul; Vol. 37 (4), pp. 1184-1193. Date of Electronic Publication: 2024 Apr 04. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Springer Country of Publication: Japan NLM ID: 8912329 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1749-0774 (Electronic) Linking ISSN: 09147470 NLM ISO Abbreviation: Hum Cell Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2011- : Tokyo : Springer Original Publication: Tōkyō-to : Hito Saibō Kenkyūkai : Kanishobo, Shōwa 63-nen [1988]- |
مواضيع طبية MeSH: | Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/pathology , Class I Phosphatidylinositol 3-Kinases*/genetics , Adenocarcinoma, Clear Cell*/genetics , Adenocarcinoma, Clear Cell*/pathology, Humans ; Female ; Cell Line, Tumor ; Middle Aged ; Transcription Factors/genetics ; Transcription Factors/metabolism ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; Nuclear Proteins/genetics ; Nuclear Proteins/metabolism ; Mutation/genetics ; Point Mutation/genetics ; Cell Proliferation/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Phosphatidylinositol 3-Kinases/genetics |
مستخلص: | A human ovarian clear cell carcinoma cell line was established from a 46-year-old Japanese woman. That line, designated MTC-22, has proliferated continuously for over 6 months in conventional RPMI 1640 medium supplemented with 10% foetal bovine serum and has been passaged over 50 times. MTC-22 doubling-time is ~ 18 h, which is much shorter than most ovarian clear cell carcinoma lines reported to date. Morphologically, MTC-22 cells exhibit polygonal shapes and proliferate to form a monolayer in a jigsaw puzzle-like arrangement without contact inhibition. Ultrastructurally, cells exhibit numerous intracytoplasmic glycogen granules and well-developed mitochondria. G-band karyotype analysis indicated that cells have a complex karyotype close to tetraploid. We observed that the expression pattern of a series of ovarian carcinoma-related molecules in MTC-22 cells was identical to that seen in the patient's tumour tissue. Notably, MTC-22 cells, and the patient's carcinoma tissue, expressed low-sulphated keratan sulphate recognised by R-10G and 294-1B1 monoclonal antibodies, a hallmark of non-mucinous ovarian carcinoma, and particularly of clear cell ovarian carcinoma. Moreover, characteristic point mutations-one in ARID1A, which encodes the AT-rich interaction domain containing protein 1A, and the other in PIK3CB, which encodes the catalytic subunit of phosphoinositide 3-kinase-were seen in the patient's tumour tissue and retained in MTC-22 cells. Collectively, these findings indicate that MTC-22 cells could serve as a valuable tool for investigating the pathophysiology of ovarian clear cell carcinoma, particularly that harbouring PIK3CB mutations, and for developing and validating new diagnostic and therapeutic approaches to this life-threatening malignancy. (© 2024. The Author(s).) |
References: | Cell. 2015 May 21;161(5):1215-1228. (PMID: 26000489) Lung. 2022 Jun;200(3):339-346. (PMID: 35394203) Gynecol Oncol. 2021 Sep;162(3):741-750. (PMID: 34247767) Clin Cancer Res. 2003 Feb;9(2):845-52. (PMID: 12576458) Gynecol Oncol. 2012 Sep;126(3):481-90. (PMID: 22525820) Urol Oncol. 2015 Nov;33(11):496.e1-9. (PMID: 26137907) Sci Rep. 2020 Oct 15;10(1):17503. (PMID: 33060611) Histopathology. 2014 Jun;64(7):1004-13. (PMID: 24329781) Am J Pathol. 2009 May;174(5):1597-601. (PMID: 19349352) Exp Mol Pathol. 2022 Jun;126:104762. (PMID: 35390310) Hum Cell. 2005 Sep;18(3):143-6. (PMID: 17022146) Ann Surg Oncol. 2006 Aug;13(8):1156-61. (PMID: 16791447) Glycobiology. 2024 Mar 19;34(1):. (PMID: 37440446) Cancer Med. 2018 Sep;7(9):4744-4754. (PMID: 30109783) N Engl J Med. 2010 Oct 14;363(16):1532-43. (PMID: 20942669) Int J Gynecol Cancer. 2021 Apr;31(4):605-616. (PMID: 32948640) Nat Rev Dis Primers. 2016 Aug 25;2:16061. (PMID: 27558151) PLoS One. 2012;7(11):e50519. (PMID: 23226302) Mod Pathol. 2011 Jun;24(6):751-64. (PMID: 21317881) Signal Transduct Target Ther. 2017 Dec 22;2:17063. (PMID: 29279775) J Exp Clin Cancer Res. 2023 Oct 7;42(1):260. (PMID: 37803448) J Histochem Cytochem. 2023 Oct;71(10):555-563. (PMID: 37675782) Cytogenet Genome Res. 2021;161(5):225-226. (PMID: 34407535) Gene Ther. 2011 Sep;18(9):857-66. (PMID: 21490680) Science. 2010 Oct 8;330(6001):228-31. (PMID: 20826764) Am J Gastroenterol. 2007 Jul;102(7):1499-509. (PMID: 17459027) Nat Commun. 2015 Jun 17;6:7419. (PMID: 26080861) Glycobiology. 2013 Mar;23(3):322-36. (PMID: 23154990) Gynecol Oncol. 2006 Aug;102(2):285-91. (PMID: 16516283) |
معلومات مُعتمدة: | 21H02702 Japan Society for the Promotion of Science |
فهرسة مساهمة: | Keywords: ARID1A; PIK3CB; Cell line; Clear cell carcinoma; Keratan sulphate; Ovary |
المشرفين على المادة: | EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) EC 2.7.1.137 (PIK3CA protein, human) 0 (ARID1A protein, human) 0 (Transcription Factors) 0 (DNA-Binding Proteins) 0 (Nuclear Proteins) EC 2.7.1.- (Phosphatidylinositol 3-Kinases) |
تواريخ الأحداث: | Date Created: 20240404 Date Completed: 20240623 Latest Revision: 20240711 |
رمز التحديث: | 20240711 |
مُعرف محوري في PubMed: | PMC11194194 |
DOI: | 10.1007/s13577-024-01058-x |
PMID: | 38573494 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1749-0774 |
---|---|
DOI: | 10.1007/s13577-024-01058-x |